McKesson (NYSE:MCK) Releases FY 2027 Earnings Guidance

McKesson (NYSE:MCK) issued an update on its FY 2027 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 43.800-44.600 for the period, compared to the consensus estimate of 44.130. The company issued revenue guidance of -.

McKesson Trading Up 1.3%

NYSE:MCK opened at $753.43 on Friday. The firm has a market capitalization of $92.29 billion, a price-to-earnings ratio of 21.67, a PEG ratio of 1.07 and a beta of 0.35. The firm’s fifty day simple moving average is $883.74 and its 200 day simple moving average is $859.93. McKesson has a twelve month low of $637.00 and a twelve month high of $999.00.

McKesson (NYSE:MCK) last released its quarterly earnings results on Thursday, May 7th. The company reported $11.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.56 by $0.13. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. The firm had revenue of $96.30 billion for the quarter, compared to the consensus estimate of $101.35 billion. During the same quarter in the previous year, the firm posted $10.12 EPS. The firm’s quarterly revenue was up 6.0% on a year-over-year basis. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. On average, analysts predict that McKesson will post 39.02 earnings per share for the current year.

McKesson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, July 1st. Stockholders of record on Monday, June 1st will be given a $0.82 dividend. The ex-dividend date of this dividend is Monday, June 1st. This represents a $3.28 annualized dividend and a dividend yield of 0.4%. McKesson’s payout ratio is presently 9.43%.

Analyst Upgrades and Downgrades

MCK has been the subject of several research analyst reports. Mizuho boosted their target price on shares of McKesson from $880.00 to $885.00 and gave the stock a “neutral” rating in a research report on Thursday, February 5th. Robert W. Baird set a $968.00 target price on shares of McKesson in a research report on Wednesday, January 14th. Leerink Partners reissued an “outperform” rating and issued a $1,085.00 target price on shares of McKesson in a research report on Thursday, March 5th. Wall Street Zen raised shares of McKesson from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Finally, Bank of America dropped their target price on shares of McKesson from $1,040.00 to $1,000.00 and set a “buy” rating for the company in a research report on Monday, April 6th. Fourteen analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $972.27.

Insider Activity

In other news, EVP Michele Lau sold 2,725 shares of McKesson stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $990.00, for a total value of $2,697,750.00. Following the completion of the transaction, the executive vice president directly owned 3,247 shares of the company’s stock, valued at approximately $3,214,530. The trade was a 45.63% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Leann B. Smith sold 190 shares of McKesson stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $945.00, for a total transaction of $179,550.00. Following the completion of the transaction, the executive vice president directly owned 2,989 shares of the company’s stock, valued at $2,824,605. This trade represents a 5.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 3,264 shares of company stock valued at $3,205,315. Company insiders own 0.08% of the company’s stock.

McKesson News Summary

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: EPS beat and operating momentum — McKesson reported $11.69 non‑GAAP EPS (above consensus) and EPS improved year‑over‑year, supporting near‑term profitability visibility. McKesson (MCK) Surpasses Q4 Earnings Estimates
• Positive Sentiment: FY‑2027 guidance implies modest upside and highlights specialty/drug distribution strength — Company guidance range implies a midpoint roughly in line with or slightly above Street estimates and management called out oncology and specialty drug businesses as primary growth drivers. McKesson expects 2027 profit slightly above estimates on drug distribution strength
• Positive Sentiment: Analyst support — William Blair reiterated an Outperform/Buy stance citing durable earnings power and the FY‑2027 growth outlook, which can bolster investor confidence. McKesson: Durable Earnings Power and Fiscal 2027 Growth Outlook Underpin Buy Rating Despite Near-Term Revenue Softness
• Neutral Sentiment: Investor materials made available — Company posted the press release, slide deck and will host an archived webcast; useful for modeling details and Q&A. McKesson Reports Fiscal 2026 Fourth Quarter and Full Year Results, Provides Fiscal 2027 Guidance, and Reaffirms Long-Term Financial Growth Targets
• Negative Sentiment: Revenue missed expectations — Quarterly revenue of $96.3B was below consensus (~$101.4B), a downside that may pressure near‑term top‑line sentiment despite EPS strength. McKesson (NYSE:MCK) Misses Q1 CY2026 Revenue Estimates
• Negative Sentiment: Sector headwinds and insider/ institutional selling — Pre‑earnings group weakness in drug distributors and recent insider/institutional reductions added pressure going into the print and remain a risk for sentiment. McKesson slides as drug-distributor sentiment sours ahead of earnings

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. State Street Corp boosted its stake in McKesson by 0.9% during the 3rd quarter. State Street Corp now owns 5,750,519 shares of the company’s stock valued at $4,447,110,000 after purchasing an additional 51,510 shares during the period. Northern Trust Corp raised its position in shares of McKesson by 0.4% during the 3rd quarter. Northern Trust Corp now owns 1,532,856 shares of the company’s stock worth $1,184,193,000 after buying an additional 6,613 shares in the last quarter. Boston Partners raised its position in shares of McKesson by 6.7% during the 3rd quarter. Boston Partners now owns 1,330,953 shares of the company’s stock worth $1,027,569,000 after buying an additional 83,357 shares in the last quarter. Invesco Ltd. raised its position in shares of McKesson by 9.5% during the 4th quarter. Invesco Ltd. now owns 1,052,739 shares of the company’s stock worth $863,551,000 after buying an additional 90,982 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of McKesson by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 934,164 shares of the company’s stock worth $766,285,000 after buying an additional 15,974 shares in the last quarter. 85.07% of the stock is owned by institutional investors and hedge funds.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.